Celldex Therapeutics Limited

Medarex Inc.

Mederex, Inc.

Joel Goldstein

Tibor P Keler

Robert F Graziano

Yashwant M Deo

Henry C Marsh

Laura A Vitale

Lizhen He

Lawrence J Thomas

Karuna Sundarapandiyan

Tom O'Neill

Andrea Crocker

Jenifer Widger

Chezian Somasundaram

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Agonistic antibodies that bind human CD40 and uses thereof

Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.

Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs

Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies

Nucleic acids encoding agonistic antibodies that bind CD40

Agonistic antibodies that bind CD40

Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.

Cells expressing anti-Fc receptor binding components

Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.

Therapeutic compounds comprised of anti-Fc receptor antibodies

Multispecific molecules which target immune cells are disclosed. The molecules are &ldquo;multispecific&rdquo; because they bind to multiple (two or more), distinct targets, one of which is a molecule on the surface of an immune cell. Multispecific molecules of the invention include molecules comprised of at least one portion which binds to a molecule on an effector cell, such as an Fc receptor, and at least one portion (e.g., two, three, four or more portions) which binds to a different target, such as an antigen on a tumor cell or a pathogen. Multispecific molecules of the invention also include antigen &ldquo;multimer complexes&rdquo; comprised of multiple (i.e., two or more) portions which bind to a molecule on an antigen presenting cell (APC), such as an Fc receptor, linked to one or more antigens. These multimer complexes target antigens, such as self-antigens, to APCs to induce and/or enhance internalization (endocytosis), processing and/or presentation of the antigen by the APC. Therefore, these molecules can be used to induce or enhance an immune response either in vivo or in vitro against a normally non-immunogenic protein, such as a self-antigen.

Therapeutic compounds comprised of anti-FC receptor binding agents

Growing community of inventors

Hopewell, NJ, United States of America

Joel Goldstein